The Centers for Medicare & Medicaid Services today announced final changes to Medicare Advantage and Part D payment policies for calendar year 2019. CMS anticipates the MA plans and Part D sponsors will see an average revenue increase of 3.4%, excluding an expected 3.1% increase in risk scores. CMS finalized changes to the risk adjustment model for aged and disabled beneficiaries enrolled in MA Part C plans beginning in CY 2019, as required by the 21st Century Cures Act, and additional changes to MA and Part D payment policies for CY 2019. CMS must phase in the new risk adjustment model over four years and will use a 25% to 75% blend of the new and previous risk adjustment model for 2019. In addition, the agency will update the MA risk adjustment models for end-stage renal disease plans in 2019, among other changes. However, CMS will not move forward with the proposed changes to the Part D risk adjustment model. The agency also included several changes to combat opioid overuse. AHA will provide more information on the final changes to members soon.

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Perspective
Public
Three key House committees — Energy and Commerce, Ways and Means, and Agriculture — after long debates and discussions this week advanced their portions of a…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
Zaira Khalid, M.D., senior staff geriatric psychiatrist at Henry Ford Behavioral Health Hospital, discusses the unique physical, emotional and social needs of…
Headline
The Department of Health and Human Services May 13 announced a 60-day public comment period opened for stakeholders regarding its request for information to…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…